An Efficacy and Safety Study of JYP0061 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial
Latest Information Update: 24 Mar 2025
At a glance
- Drugs JYP-0061 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Guangzhou JOYO Pharma
- 20 Mar 2025 Planned End Date changed from 10 Feb 2025 to 10 Feb 2026.
- 20 Mar 2025 Planned primary completion date changed from 10 Feb 2025 to 10 Feb 2026.
- 14 Nov 2024 Status changed from not yet recruiting to recruiting.